Form 4: Lyell Immunopharma Insider Reports Stock Transaction
Insider Transaction (Form 4)
Innovative Cellular Therapeutics Holdings Ltd reported changes in beneficial ownership of Lyell Immunopharma, Inc. common stock on July 27, 2026.
Summary
- Other acquisition/disposition: disposed of 44,000 Common Stock on July 27, 2026; holds 2,774,980 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Innovative Cellular Therapeutics Holdings Ltd — 10% owner
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-27 | Other acquisition/disposition | Common Stock | 44,000 | — | — | 2,774,980 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-27 | Other acquisition/disposition (44,000 shares) |
Keywords
insider transaction, Form 4, LYEL, Lyell Immunopharma, Inc., neutral, Innovative Cellular Therapeutics Holdings Ltd
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.